Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Kinase inhibitors for advanced medullary thyroid carcinoma.

Schlumberger M, Massicotte MH, Nascimento CL, Chougnet C, Baudin E, Leboulleux S.

Clinics (Sao Paulo). 2012;67 Suppl 1:125-9. Review.

2.

Vandetanib and the management of advanced medullary thyroid cancer.

Campbell MJ, Seib CD, Gosnell J.

Curr Opin Oncol. 2013 Jan;25(1):39-43. doi: 10.1097/CCO.0b013e32835a42b9. Review.

PMID:
23202050
3.

[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].

Chougnet CN, Schlumberger M, Leboulleux S, Baudin E.

Bull Cancer. 2014 Sep;101(9):891-5. doi: 10.1684/bdc.2014.2022. Review. French.

PMID:
25296193
4.

Vandetanib for the treatment of medullary thyroid cancer.

Chau NG, Haddad RI.

Clin Cancer Res. 2013 Feb 1;19(3):524-9. doi: 10.1158/1078-0432.CCR-12-2353. Epub 2012 Dec 11. Review.

5.

Vandetanib for the treatment of medullary thyroid carcinoma.

Cooper MR, Yi SY, Alghamdi W, Shaheen DJ, Steinberg M.

Ann Pharmacother. 2014 Mar;48(3):387-94. doi: 10.1177/1060028013512791. Epub 2013 Nov 14. Review.

PMID:
24259657
6.

Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.

Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R.

J Clin Endocrinol Metab. 2010 Jun;95(6):2664-71. doi: 10.1210/jc.2009-2461. Epub 2010 Apr 6.

7.

Vandetanib: a guide to its use in advanced medullary thyroid cancer.

Keating GM, Lyseng-Williamson KA, Frampton JE.

BioDrugs. 2012 Dec 1;26(6):431-5. doi: 10.2165/11209360-000000000-00000. Review.

PMID:
22938056
8.

The safety of vandetanib for the treatment of thyroid cancer.

Tsang VH, Robinson BG, Learoyd DL.

Expert Opin Drug Saf. 2016 Aug;15(8):1107-13. doi: 10.1080/14740338.2016.1201060. Epub 2016 Jul 4. Review.

PMID:
27301016
9.

The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.

Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A.

Expert Rev Anticancer Ther. 2016 Nov;16(11):1109-1118. Epub 2016 Sep 30. Review.

PMID:
27650489
10.

Molecular targeted therapies for patients with refractory thyroid cancer.

Chougnet C, Brassard M, Leboulleux S, Baudin E, Schlumberger M.

Clin Oncol (R Coll Radiol). 2010 Aug;22(6):448-55. doi: 10.1016/j.clon.2010.04.008. Review.

PMID:
20554167
11.

Updates in the management of medullary thyroid cancer.

Hu MI.

Clin Adv Hematol Oncol. 2011 May;9(5):391-4. No abstract available.

PMID:
21685868
12.

Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.

Jalalat SZ, Cohen PR.

Int J Dermatol. 2015 Jun;54(6):e213-6. doi: 10.1111/ijd.12289. Epub 2014 Jul 11. No abstract available.

PMID:
25040327
13.

Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.

Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.

Thyroid. 2015 Apr;25(4):386-91. doi: 10.1089/thy.2014.0361. Epub 2015 Feb 18.

PMID:
25627619
14.

Advanced thyroid cancers: new era of treatment.

Mohammed AA, El-Shentenawy A.

Med Oncol. 2014 Jul;31(7):49. doi: 10.1007/s12032-014-0049-x. Epub 2014 Jun 8. Review.

PMID:
24908065
15.

Targeted molecular therapies in thyroid carcinoma.

Romagnoli S, Moretti S, Voce P, Puxeddu E.

Arq Bras Endocrinol Metabol. 2009 Dec;53(9):1061-73. Review.

16.

Photo-induced erythema multiforme associated with vandetanib administration.

Caro-Gutiérrez D, Floristán Muruzábal MU, Gómez de la Fuente E, Franco AP, López Estebaranz JL.

J Am Acad Dermatol. 2014 Oct;71(4):e142-4. doi: 10.1016/j.jaad.2014.05.003. No abstract available.

17.

Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.

Fagin JA, Tuttle RM, Pfister DG.

J Clin Endocrinol Metab. 2010 Jun;95(6):2621-4. doi: 10.1210/jc.2010-0800. No abstract available.

18.

Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.

Tiedje V, Ting S, Walter RF, Herold T, Worm K, Badziong J, Zwanziger D, Schmid KW, Führer D.

Eur J Endocrinol. 2016 Sep;175(3):173-80. doi: 10.1530/EJE-16-0252. Epub 2016 Jun 9.

PMID:
27283290
19.

Selective use of vandetanib in the treatment of thyroid cancer.

Fallahi P, Di Bari F, Ferrari SM, Spisni R, Materazzi G, Miccoli P, Benvenga S, Antonelli A.

Drug Des Devel Ther. 2015 Jul 3;9:3459-70. doi: 10.2147/DDDT.S72495. eCollection 2015. Review.

20.

Multikinase inhibitors in thyroid cancer.

Licitra L, Locati LD.

Ann Oncol. 2012 Sep;23 Suppl 10:x328-33. No abstract available.

PMID:
22987985

Supplemental Content

Support Center